Synopsis : IPCA Laboratories is attracting renewed investor interest after Emkay Global maintained its ‘Buy’ rating and raised its target price to Rs.1,800, indicating a potential upside of 21%. Strong Q4FY26 earnings, an improving growth outlook, expected margin expansion, and a robust product launch pipeline are key factors supporting the brokerage's positive view on the pharmaceutical major.
IPCA Laboratories has received a fresh vote of confidence from Emkay Global Financial Services, which has reaffirmed its ‘Buy’ rating on the stock and increased its target price to Rs.1,800 from Rs.1,700. The revised target suggests an upside potential of nearly 21% from current market levels, driven by strong earnings performance, healthy growth prospects, and improving profitability.
The brokerage highlighted IPCA’s impressive Q4FY26 results, where the company delivered better-than-expected operating performance. Consolidated EBITDA exceeded market estimates, supported by stronger sales growth, improved gross margins, and lower-than-anticipated employee expenses. A standout performer was the generic formulations segment, which recorded a robust 39% year-on-year growth, significantly surpassing analyst expectations.
Management remains optimistic about the company’s future growth trajectory and has guided for consolidated revenue growth of 12–13% in FY27. A key contributor is expected to be Unichem’s US business, which is projected to grow around 10% as it gradually regains market share and strengthens its presence in the highly competitive pharmaceutical market.
Emkay also expects a meaningful improvement in profitability over the coming years. The brokerage forecasts consolidated EBITDA margins to reach nearly 22%, supported by operating leverage benefits, steady domestic volume growth, and efficiency gains from restructuring initiatives. The closure of Unichem’s Ireland manufacturing facility and the transfer of production to India are expected to further enhance margins and operational efficiency.
Another major growth driver is IPCA’s strong product launch pipeline. The company plans to launch 6–8 new products in the United States through IPCA and an additional 5–6 products through Unichem during FY27. It also aims to introduce multiple products across Europe and other international generic markets, strengthening its global footprint and diversifying revenue streams.
According to Emkay, a recent correction in the stock price has created an attractive valuation opportunity. The brokerage believes a significant gap has emerged between the company's intrinsic value and its current market price, making the stock appealing even under conservative growth and margin assumptions.
IPCA Laboratories reported a strong set of numbers for the March quarter. Consolidated net profit surged to Rs.299.07 crore, while revenue increased 6.3% year-on-year to Rs.2,388.5 crore. EBITDA rose 12.7% to Rs.484 crore, with operating margins expanding to 20.2% compared to 19% in the corresponding period last year.
Adding to shareholder value, the company's board has also proposed a dividend of Rs.6 per share for FY26.
With strong earnings momentum, improving margins, expanding global opportunities, and a healthy product pipeline, analysts believe IPCA Laboratories remains well-positioned to deliver sustainable growth in the coming years.
Disclaimer : This article is for informational and educational purposes only and should not be considered financial or investment advice. Investors should consult a SEBI-registered financial advisor before making any investment decisions.
